CLDN7 and hepatocellular carcinoma: To further investigate the molecular mechanism, we added proteasome specific inhibitor MG132 to HCC cells and found that MG132 protected Claudin1 from degradation (Fig. 5A, C), suggesting that the degradation of Claudin1 protein is carried out through the proteasomal pathway.